Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus TACE in resectable advanced hepatocellular carcinoma
NCT04143191Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04143191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143191.